134 related articles for article (PubMed ID: 34339817)
1. Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma.
Mannarino L; Craparotta I; Ballabio S; Frapolli R; Meroni M; Bello E; Panini N; Callari M; Sanfilippo R; Casali PG; Barisella M; Fabbroni C; Marchini S; D'Incalci M
Genomics; 2021 Sep; 113(5):3439-3448. PubMed ID: 34339817
[TBL] [Abstract][Full Text] [Related]
2. Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.
Bello E; Brich S; Craparotta I; Mannarino L; Ballabio S; Gatta R; Marchini S; Carrassa L; Matteo C; Sanfilippo R; Gronchi A; Casali PG; Pilotti S; D'Incalci M; Frapolli R
Br J Cancer; 2019 Sep; 121(6):464-473. PubMed ID: 31409911
[TBL] [Abstract][Full Text] [Related]
3. A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma.
Uboldi S; Calura E; Beltrame L; Fuso Nerini I; Marchini S; Cavalieri D; Erba E; Chiorino G; Ostano P; D'Angelo D; D'Incalci M; Romualdi C
PLoS One; 2012; 7(4):e35423. PubMed ID: 22523595
[TBL] [Abstract][Full Text] [Related]
4. Mode of action of trabectedin in myxoid liposarcomas.
Di Giandomenico S; Frapolli R; Bello E; Uboldi S; Licandro SA; Marchini S; Beltrame L; Brich S; Mauro V; Tamborini E; Pilotti S; Casali PG; Grosso F; Sanfilippo R; Gronchi A; Mantovani R; Gatta R; Galmarini CM; Sousa-Faro JM; D'Incalci M
Oncogene; 2014 Oct; 33(44):5201-10. PubMed ID: 24213580
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.
Uboldi S; Bernasconi S; Romano M; Marchini S; Fuso Nerini I; Damia G; Ganzinelli M; Marangon E; Sala F; Clivio L; Chiorino G; Di Giandomenico S; Rocchi M; Capozzi O; Margison GP; Watson AJ; Caccuri AM; Pastore A; Fossati A; Mantovani R; Grosso F; Tercero JC; Erba E; D'Incalci M
Int J Cancer; 2012 Jul; 131(1):59-69. PubMed ID: 21805478
[TBL] [Abstract][Full Text] [Related]
6. Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.
Frapolli R; Tamborini E; Virdis E; Bello E; Tarantino E; Marchini S; Grosso F; Sanfilippo R; Gronchi A; Tercero JC; Peloso G; Casali P; Pilotti S; D'Incalci M
Clin Cancer Res; 2010 Oct; 16(20):4958-67. PubMed ID: 20732964
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
Grosso F; Jones RL; Demetri GD; Judson IR; Blay JY; Le Cesne A; Sanfilippo R; Casieri P; Collini P; Dileo P; Spreafico C; Stacchiotti S; Tamborini E; Tercero JC; Jimeno J; D'Incalci M; Gronchi A; Fletcher JA; Pilotti S; Casali PG
Lancet Oncol; 2007 Jul; 8(7):595-602. PubMed ID: 17586092
[TBL] [Abstract][Full Text] [Related]
8. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.
Forni C; Minuzzo M; Virdis E; Tamborini E; Simone M; Tavecchio M; Erba E; Grosso F; Gronchi A; Aman P; Casali P; D'Incalci M; Pilotti S; Mantovani R
Mol Cancer Ther; 2009 Feb; 8(2):449-57. PubMed ID: 19190116
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma.
Assi T; Kattan J; El Rassy E; Honore C; Dumont S; Mir O; Le Cesne A
Cancer Treat Rev; 2019 Jan; 72():37-44. PubMed ID: 30468937
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1.
Dossi R; Frapolli R; Di Giandomenico S; Paracchini L; Bozzi F; Brich S; Castiglioni V; Borsotti P; Belotti D; Uboldi S; Sanfilippo R; Erba E; Giavazzi R; Marchini S; Pilotti S; D'Incalci M; Taraboletti G
Int J Cancer; 2015 Feb; 136(3):721-9. PubMed ID: 24917554
[TBL] [Abstract][Full Text] [Related]
11. Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas.
Frapolli R; Bello E; Ponzo M; Craparotta I; Mannarino L; Ballabio S; Marchini S; Carrassa L; Ubezio P; Porcu L; Brich S; Sanfilippo R; Casali PG; Gronchi A; Pilotti S; D'Incalci M
Clin Cancer Res; 2019 Dec; 25(24):7565-7575. PubMed ID: 31481505
[TBL] [Abstract][Full Text] [Related]
12. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.
D'Incalci M; Badri N; Galmarini CM; Allavena P
Br J Cancer; 2014 Aug; 111(4):646-50. PubMed ID: 24755886
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models.
Martinez-Cruzado L; Tornin J; Rodriguez A; Santos L; Allonca E; Fernandez-Garcia MT; Astudillo A; Garcia-Pedrero JM; Rodriguez R
Neoplasia; 2017 Jun; 19(6):460-470. PubMed ID: 28494349
[TBL] [Abstract][Full Text] [Related]
14. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
Germano G; Frapolli R; Simone M; Tavecchio M; Erba E; Pesce S; Pasqualini F; Grosso F; Sanfilippo R; Casali PG; Gronchi A; Virdis E; Tarantino E; Pilotti S; Greco A; Nebuloni M; Galmarini CM; Tercero JC; Mantovani A; D'Incalci M; Allavena P
Cancer Res; 2010 Mar; 70(6):2235-44. PubMed ID: 20215499
[TBL] [Abstract][Full Text] [Related]
15. DNA damage-inducible transcript 3 immunohistochemistry is highly sensitive for the diagnosis of myxoid liposarcoma but care is required in interpreting the significance of focal expression.
Vargas AC; Chan NL; Wong DD; Zaborowski M; Fuchs TL; Ahadi M; Clarkson A; Sioson L; Sheen A; Maclean F; Bonar F; Cheah A; Jones M; Chou A; Gill AJ
Histopathology; 2021 Jul; 79(1):106-116. PubMed ID: 33465826
[TBL] [Abstract][Full Text] [Related]
16. FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma.
Trautmann M; Menzel J; Bertling C; Cyra M; Isfort I; Steinestel K; Elges S; Grünewald I; Altvater B; Rossig C; Fröhling S; Hafner S; Simmet T; Åman P; Wardelmann E; Huss S; Hartmann W
Clin Cancer Res; 2017 Oct; 23(20):6227-6238. PubMed ID: 28637688
[No Abstract] [Full Text] [Related]
17. Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG).
Gronchi A; Palmerini E; Quagliuolo V; Martin Broto J; Lopez Pousa A; Grignani G; Brunello A; Blay JY; Tendero O; Diaz Beveridge R; Ferraresi V; Lugowska I; Pizzamiglio S; Verderio P; Fontana V; Donati DM; Palassini E; Sanfilippo R; Bianchi G; Bertuzzi A; Morosi C; Pasquali S; Stacchiotti S; Bagué S; Coindre JM; Miceli R; Dei Tos AP; Casali PG
J Clin Oncol; 2024 Mar; 42(8):898-906. PubMed ID: 38232337
[TBL] [Abstract][Full Text] [Related]
18. Expression of CTAG1B clone EPR13780 versus
Abdelaziz MM; Tayel HY; Abdel-Bary A; Badawy OM
J Histotechnol; 2022 Jun; 45(2):56-65. PubMed ID: 34845972
[TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of two novel patient-derived myxoid liposarcoma cell lines.
Noguchi R; Yoshimatsu Y; Sin Y; Tsuchiya R; Ono T; Akiyama T; Hirabayashi K; Ozawa I; Nakagawa R; Kikuta K; Kondo T
Hum Cell; 2022 Jul; 35(4):1279-1289. PubMed ID: 35637403
[TBL] [Abstract][Full Text] [Related]
20. The utility of fluorescence in situ hybridization (FISH) in determining DNA damage-inducible transcript 3 (DDIT3) amplification in dedifferentiated liposarcomas - an important diagnostic pitfall.
Kuczkiewicz-Siemion O; Wiśniewski P; Dansonka-Mieszkowska A; Grabowska-Kierył M; Olszewska K; Goryń T; Prochorec-Sobieszek M; Rutkowski P; Szumera-Ciećkiewicz A
Pathol Res Pract; 2021 Sep; 225():153555. PubMed ID: 34325315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
